NZReta Editorial Policy
This page explains how NZReta researches, writes, reviews, updates and corrects educational content about retatrutide, clinical trial data, Medsafe status, fake-product risks and New Zealand-specific safety context.
Why this page exists.
Retatrutide is an investigational medicine, so clarity matters. This editorial policy sets out how NZReta handles evidence, uncertainty, regulatory status, corrections and reader safety.
Clear, New Zealand-Focused Retatrutide Education
NZReta publishes educational content for New Zealand readers about retatrutide, GLP-1 medicines, clinical trial data, Medsafe status, peptide safety issues, fake-product risks and COA verification basics.
Our goal is to help readers understand the current evidence, legal status, safety concerns and regulatory context around retatrutide and related compounds.
NZReta does not provide medical advice, prescribing advice, personal dosing instructions, sourcing advice or product recommendations.
Retatrutide is not an approved consumer medicine in New Zealand. Our content is written to help readers understand that distinction clearly.
What NZReta Covers
NZReta may publish guides, explainers, status updates and comparison pages on topics such as:
Trial data and mechanism
Retatrutide clinical trial results, mechanism of action, GLP-1, GIP and glucagon receptor science and comparisons with medicines such as semaglutide and tirzepatide.
Status and safety context
Medsafe status, regulatory context, fake-product risks, COA red flags, approved medicine pathways and New Zealand-specific availability questions.
We do not publish content that is intended to replace advice from a doctor, pharmacist, lawyer, regulator or other qualified professional.
Medical and Legal Disclaimer
NZReta content is for general educational purposes only.
Nothing on this website should be treated as medical advice, legal advice, prescribing advice, dosing advice, sourcing advice or a recommendation to use retatrutide or any other unapproved medicine.
Readers should speak with a qualified health professional before making decisions about weight-loss treatment, medication, injections or peptide use.
Readers with legal or regulatory questions should seek professional legal advice or consult official New Zealand government sources.
Clinical trial results do not mean a medicine is approved, available, safe for unsupervised use or suitable for every person.
How We Research Content
NZReta articles are written using publicly available sources and are checked for clarity, source quality and New Zealand relevance before publication.
Our research process may include reviewing:
- Medsafe and New Zealand Ministry of Health information
- Official pharmaceutical company announcements
- Peer-reviewed clinical trial publications
- Clinical trial registries
- Recognised medical and scientific publications
- New Zealand health-information sources
- Official regulatory updates
- Relevant product-safety warnings
When evidence is uncertain, early-stage, incomplete or not directly applicable to New Zealand, we aim to say so clearly.
Source Standards
NZReta prioritises primary and authoritative sources wherever possible.
We avoid relying on anonymous claims, seller claims, social media posts or unsourced marketing material as evidence for medical, legal or safety statements.
| Source Type | How We Use It |
|---|---|
| Official regulators | Used for legal status, safety warnings, approval context and New Zealand-specific regulatory information. |
| Clinical trial records | Used to explain trial phase, participant groups, study design, endpoints and whether a trial is recruiting or complete. |
| Peer-reviewed journals | Used for clinical outcomes, adverse-event data, mechanistic explanations and evidence-based comparisons. |
| Company announcements | Used for topline results and development timelines, with clear wording when data has not yet been fully peer reviewed. |
| Market or seller claims | Not used as proof of safety, legality, purity, approval or suitability. These claims may be discussed only as part of fake-product or consumer-risk education. |
How We Present Clinical Trial Data
NZReta aims to describe clinical trial findings accurately and in context.
Where relevant, articles should identify the trial phase, study population, treatment duration, dosage groups, primary endpoints and whether the results are peer reviewed.
Percentage weight-loss figures should not be presented without enough context for readers to understand what the number represents.
We aim to distinguish between:
- Average trial results and individual outcomes
- Completed trials and ongoing studies
- Peer-reviewed evidence and company-reported topline data
- Statistical findings and guaranteed personal outcomes
- Investigational medicines and approved treatments
Legal and Regulatory Information
NZReta aims to present New Zealand legal and regulatory information carefully and without overstating what the law means for an individual reader.
Medsafe, the New Zealand Ministry of Health, the Medicines Act, official medicine databases and other government sources are prioritised when discussing approval, classification, advertising, importation or supply.
We do not provide instructions for avoiding regulation, importing restricted products unlawfully or sourcing unapproved medicines for personal use.
When discussing New Zealand status, our pages should avoid implying that trial data, COAs, overseas supply or “research use only” language makes a product approved, safe or suitable for consumer use.
Authors, Review and Page Transparency
NZReta content is written by the NZReta Editorial Team.
Each major guide should display the author or editorial team, the publication or last-updated date, the main sources used and an appropriate disclaimer where medical or legal topics are discussed.
Where appropriate, NZReta may seek external review from people with relevant health, science, legal or regulatory knowledge.
If a named reviewer is added to a guide, the page should identify their role or relevant expertise clearly.
Review, Updates and Corrections
NZReta reviews important pages when major new information becomes available.
This may include:
- Medsafe or Ministry of Health updates
- Major clinical trial readouts
- Peer-reviewed trial publications
- Pharmaceutical company announcements
- Changes to New Zealand medicine availability
- Significant safety warnings
- Corrections or reader feedback
High-priority pages, such as legal-status, safety, clinical-trial and comparison guides, may be reviewed more frequently than general background pages.
NZReta aims to correct factual errors promptly.
If a correction materially changes the meaning of a page, we may update the visible “last updated” date and clarify the change within the content where appropriate.
Commercial Transparency and Email Forms
NZReta may collect email signups for educational updates, including retatrutide status updates, trial-data summaries, Medsafe-related developments and fake-product warnings.
NZReta does not present email signup forms as medical advice, prescribing advice, sourcing advice or a guarantee of product access.
If NZReta receives compensation, sponsorship, affiliate income or any other commercial benefit connected to a page, that relationship should be disclosed clearly on the relevant page.
Email capture should not prevent readers from accessing the main content. Popups and forms should not obscure important safety or legal information.
AI-Assisted Content
NZReta may use AI-assisted tools to help draft, structure, summarise or edit content.
AI-assisted content should be checked before publication for accuracy, clarity, safety and source quality.
AI-generated text should not be treated as a source of medical, legal or scientific truth.
Important claims should be checked against authoritative sources before publication.
Feedback and Correction Requests
Readers who believe a page contains an error, outdated information, unclear wording or missing context can contact NZReta by email.
We welcome correction requests, source suggestions and feedback that helps improve the accuracy and usefulness of NZReta content.
Correction requests can be sent to nzretatrutide@proton.me .
Please include the page URL, the statement you believe should be reviewed and any supporting source you would like the editorial team to consider.
What NZReta does not do: NZReta does not provide personal medical advice, personal dosing instructions, product-source recommendations, legal advice or instructions for avoiding regulation.